Tocilizumab in COVID-19: some clarity amid controversy

[1]  Steve B Jones,et al.  Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial , 2021, Lancet.

[2]  Kang Zhang,et al.  COVID-19 in early 2021: current status and looking forward , 2021, Signal Transduction and Targeted Therapy.

[3]  I. Douglas,et al.  Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia , 2021, The New England journal of medicine.

[4]  Christopher M. Horvat,et al.  Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 , 2021, medRxiv.

[5]  W. Lim,et al.  Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .

[6]  J. Stone,et al.  Tocilizumab in Covid-19. Reply. , 2020, The New England journal of medicine.

[7]  Eric A. Meyerowitz,et al.  Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 , 2020, The New England journal of medicine.

[8]  R. Porcher,et al.  Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.

[9]  Samantha K. Brenner,et al.  Association Between Early Treatment With Tocilizumab and Mortality Among Critically Ill Patients With COVID-19. , 2020, JAMA internal medicine.

[10]  M. Massari,et al.  Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. , 2020, JAMA internal medicine.

[11]  Keith Sigel,et al.  An inflammatory cytokine signature predicts COVID-19 severity and survival , 2020, Nature Medicine.

[12]  Xiaohu Zheng,et al.  Effective treatment of severe COVID-19 patients with tocilizumab , 2020, Proceedings of the National Academy of Sciences.

[13]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)]. , 2018, Giornale italiano di cardiologia.

[14]  R. Brook,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American Society of Hypertension : JASH.

[15]  B. Carlberg,et al.  Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis , 2018, JAMA internal medicine.

[16]  S. Anderson,et al.  Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis , 2016, The Lancet.

[17]  G. Parati,et al.  Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials , 2014, Journal of hypertension.

[18]  Harry Hemingway,et al.  Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people , 2014, The Lancet.

[19]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.